Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29. Read More...
Motley Fool
Appian Just Took Another Step to a $2 Billion Award
Multibillion-dollar legal awards aren’t particularly common for publicly traded companies, so it raised eyebrows when Appian (NASDAQ: APPN) was awarded a $2.036 billion judgment over rival Pegasystems (NASDAQ: PEGA) in May. Appian, the low-code software company, sued Pegasystems for its “unjust enrichment” after the latter company hired a contractor, which it referred to internally as a “spy,” to give it trade secrets about Appian; Pegasystems then used those to train its sales force to better compete with Appian. The court also ordered Pegasystems to pay $23.6 million as reimbursement for Appian’s attorney fees.
